Status:
ACTIVE_NOT_RECRUITING
Primary Care Transfer for Thyroid Cancer Patients
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Differentiated Thyroid Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
Introduction: Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. It presents low recurrence rates (2-5%) and the consensus of DTC recommends long-term follow-up, without a de...
Detailed Description
Differentiated thyroid cancer (DTC) is the most frequent malignant neoplasm of the endocrine system, accounting for approximately 95% of the cases of carcinomas in this system. DTC is considered to be...
Eligibility Criteria
Inclusion
- Patients with diagnostic of differentiated thyroid cancer and an excellent response to the initial treatment.
Exclusion
- Definitive postoperative hypoparathyroidism.
- Postoperative vocal cord paralysis requiring tracheostomy.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT03794375
Start Date
January 1 2019
End Date
December 31 2026
Last Update
October 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil